Patents by Inventor Heidi Okamura

Heidi Okamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-NOTCH3 ANTIBODY
    Publication number: 20220235127
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.
    Type: Application
    Filed: October 7, 2021
    Publication date: July 28, 2022
    Inventors: Heidi Okamura, William M. Winston, JR., Laura Poling, Alisa C. Bell
  • Anti-Notch3 antibody
    Patent number: 11142573
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 12, 2021
    Assignee: AVEO PHARMACEUTICALS, INC.
    Inventors: Heidi Okamura, William M. Winston, Jr., Laura Poling, Alisa C. Bell
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20210171627
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: August 13, 2020
    Publication date: June 10, 2021
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • Anti-NOTCH3 antibodies
    Patent number: 10745476
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: August 18, 2020
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • ANTI-NOTCH3 ANTIBODY
    Publication number: 20190144537
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 16, 2019
    Inventors: Heidi Okamura, William M. Winston, Jr., Laura Poling, Alisa C. Bell
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20180230213
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 16, 2018
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, JR., Jeno Gyuris
  • Anti-Notch3 antibodies
    Patent number: 9879083
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 30, 2018
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20160185852
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: December 19, 2013
    Publication date: June 30, 2016
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, JR., Jeno Gyuris
  • Identifying cancers sensitive to treatment with inhibitors of notch signaling
    Patent number: 7544476
    Abstract: The disclosure provides a method for identifying cancer tissue sensitive to treatment with an inhibitor of Notch receptor activation. The method comprises determining the level of HeyL gene expression in a sample derived from the cancer tissue, wherein an elevated level of HeyL gene expression alone in the sample indicates sensitivity to the cancer tissue to treatment with an inhibitor of Notch receptor activation.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: June 9, 2009
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Ronan O'Hagan, H. Heidi Okamura, Alisa C. Bell, Jeanine Lorusso